GLOBUS MEDICAL financials
$75.69+1.22%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.94B | $2.52B | $1.57B | $1.02B | $958.1M | $789.0M | $785.4M | $713.0M | $636.0M | $564.0M |
| Gross profit | $1.98B | $1.48B | $1.02B | $759.1M | $718.9M | $571.6M | $605.4M | $553.6M | $485.5M | $429.3M |
| Gross margin | 67.4% | 58.9% | 65.1% | 74.2% | 75.0% | 72.4% | 77.1% | 77.6% | 76.3% | 76.1% |
| Operating income | $479.8M | $166.0M | $133.1M | $233.9M | $189.5M | $111.4M | $172.0M | $169.3M | $161.8M | $154.1M |
| Net income | $537.9M | $103.0M | $122.9M | $190.2M | $149.2M | $102.3M | $155.2M | $156.5M | $107.3M | $104.3M |
| Net margin | 18.3% | 4.1% | 7.8% | 18.6% | 15.6% | 13.0% | 19.8% | 21.9% | 16.9% | 18.5% |
| Diluted EPS | $3.92 | $0.75 | $1.07 | $1.85 | $1.44 | $1.01 | $1.52 | $1.54 | $1.10 | $1.08 |
| EBITDA | $814.0M | $472.8M | $346.9M | $304.5M | $265.3M | $178.3M | $229.5M | $218.5M | $208.2M | $197.9M |
| Operating cash flow | $753.4M | $520.6M | $243.5M | $173.3M | $259.5M | $196.1M | $172.0M | $181.6M | $159.1M | $117.8M |
| Free cash flow | $588.8M | $405.2M | $165.2M | $99.3M | $202.6M | $132.5M | $101.2M | $121.9M | $107.8M | $76.9M |
| Diluted shares | 137.1M | 137.9M | 114.6M | 102.6M | 103.6M | 101.0M | 102.0M | 101.3M | 97.9M | 96.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $526.2M | $784.4M | $467.3M | $150.5M | $193.1M | $239.4M |
| Short-term investments | $31.1M | $105.6M | $50.5M | $295.6M | $250.4M | $187.3M |
| Total debt | $0.00 | $443.4M | $417.4M | $0.00 | $0.00 | $0.00 |
| Total assets | $5.30B | $5.25B | $5.09B | $2.08B | $1.96B | $1.68B |
| Total liabilities | $729.5M | $1.07B | $1.09B | $229.8M | $215.9M | $173.2M |
| Shareholders' equity | $4.57B | $4.18B | $4.00B | $1.85B | $1.74B | $1.51B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology